| Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or … T Doi, K Shitara, Y Naito, A Shimomura, Y Fujiwara, K Yonemori, ... The Lancet Oncology 18 (11), 1512-1522, 2017 | 400 | 2017 |
| Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer A Kitano, M Ono, M Yoshida, E Noguchi, A Shimomura, T Shimoi, ... ESMO open 2 (2), e000150, 2017 | 143 | 2017 |
| The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition T Shimoi, SE Nagai, T Yoshinami, M Takahashi, H Arioka, M Ishihara, ... Breast Cancer 27, 322-331, 2020 | 63 | 2020 |
| The significant impact of acute kidney injury on CKD in patients who survived over 10 years after myeloablative allogeneic SCT T Shimoi, M Ando, W Munakata, T Kobayashi, K Kakihana, K Ohashi, ... Bone marrow transplantation 48 (1), 80-84, 2013 | 53 | 2013 |
| PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system T Shimoi, A Hamada, M Yamagishi, M Hirai, M Yoshida, T Nishikawa, ... Cancer science 109 (8), 2558-2566, 2018 | 48 | 2018 |
| Breast cancer brain metastasis—overview of disease state, treatment options and future perspectives C Watase, S Shiino, T Shimoi, E Noguchi, T Kaneda, Y Yamamoto, ... Cancers 13 (5), 1078, 2021 | 46 | 2021 |
| TERT promoter hotspot mutations in breast cancer T Shimoi, M Yoshida, Y Kitamura, T Yoshino, A Kawachi, A Shimomura, ... Breast Cancer 25, 292-296, 2018 | 35 | 2018 |
| Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer S Bun, M Yunokawa, Y Tamaki, A Shimomura, T Shimoi, M Kodaira, ... Supportive Care in Cancer 26, 2161-2166, 2018 | 32 | 2018 |
| Efficacy and safety of pazopanib for recurrent or metastatic solitary fibrous tumor T Ebata, T Shimoi, S Bun, M Miyake, A Yoshida, A Shimomura, E Noguchi, ... Oncology 94 (6), 340-344, 2018 | 31 | 2018 |
| 64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer S Sasada, H Kurihara, T Kinoshita, M Yoshida, N Honda, T Shimoi, ... Annals of Oncology 28 (8), 2028-2029, 2017 | 29 | 2017 |
| Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity C Udagawa, H Nakamura, H Ohnishi, K Tamura, T Shimoi, M Yoshida, ... Cancer science 109 (2), 446-452, 2018 | 27 | 2018 |
| Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors Y Takeyasu, HS Okuma, Y Kojima, T Nishikawa, M Tanioka, K Sudo, ... JCO precision oncology 5, 756-766, 2021 | 26 | 2021 |
| Cytokeratin-positive malignant tumor in the abdomen with EWSR1/FUS-CREB fusion: a clinicopathologic study of 8 cases T Shibayama, T Shimoi, T Mori, E Noguchi, Y Honma, S Hijioka, ... The American journal of surgical pathology 46 (1), 134-146, 2022 | 22 | 2022 |
| Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with … S Noda-Narita, A Shimomura, A Kawachi, H Sumiyoshi-Okuma, K Sudo, ... Breast Cancer 26, 492-498, 2019 | 22 | 2019 |
| Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors T Nishikawa, K Matsumoto, K Tamura, H Yoshida, Y Imai, A Miyasaka, ... Cancer Science 108 (9), 1834-1842, 2017 | 22 | 2017 |
| Clinical and pathological features of Churg Strauss syndrome among a Japanese population: a case series of 18 patients T Shimoi, K Shojima, A Murota, Y Takizawa, J Maruyama, K Setoguchi Asian Pacific Journal of Allergy and Immunology 30 (1), 61, 2012 | 20 | 2012 |
| Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation K Tamura, K Shitara, Y Naito, A Shimomura, Y Fujiwara, K Yonemori, ... Annals of Oncology 27, vi556, 2016 | 19 | 2016 |
| A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population MH Nakano, C Udagawa, A Shimo, Y Kojima, R Yoshie, H Zaha, N Abe, ... Biological and Pharmaceutical Bulletin 42 (12), 2045-2053, 2019 | 18 | 2019 |
| Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer M Yunokawa, H Yoshida, R Watanabe, E Noguchi, A Shimomura, ... Cancer Chemotherapy and Pharmacology 80, 127-134, 2017 | 18 | 2017 |
| Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET S Sasada, H Kurihara, T Kinoshita, M Yoshida, N Honda, T Shimoi, ... European Journal of Nuclear Medicine and Molecular Imaging 44 (12), 2146-2147, 2017 | 16 | 2017 |
Kazuki SudoNational Cancer Center, JapanVerified email at ncc.go.jp
